Seasonal Influenza

Infectious Diseases
21
Pipeline Programs
4
Companies
23
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
3
5
0
10
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
953%
RNA Therapeutic
741%
Small Molecule
16%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

BioCryst Pharmaceuticals
RAPIVABApproved
peramivir
BioCryst Pharmaceuticals
Neuraminidase Inhibitor [EPC]intravenous2014

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
11 programs
5
5
1
Cell-derived influenza vaccinePhase 4Vaccine1 trial
BEGRIVACPhase 31 trial
Influenza VaccinePhase 3Vaccine1 trial
TIVPhase 31 trial
inactivated split influenza vaccinePhase 3Vaccine2 trials
+6 more programs
Active Trials
NCT01342796Completed84Est. Feb 2012
NCT01344057Completed63Est. Jun 2011
NCT01123954Completed33Est. Apr 2010
+11 more trials
BioCryst Pharmaceuticals
1 program
1
1
PeramivirPhase 3Small Molecule1 trial
Active Trials
NCT00957996Completed234Est. Aug 2011
Moderna
ModernaCAMBRIDGE, MA
7 programs
3
4
mRNA-1010Phase 3RNA Therapeutic1 trial
mRNA-1010Phase 3RNA Therapeutic1 trial
mRNA-1010Phase 3RNA Therapeutic1 trial
mRNA-1010Phase 3RNA Therapeutic1 trial
mRNA-1010Phase 1/2RNA Therapeutic1 trial
+2 more programs
Active Trials
NCT04956575Completed885Est. Sep 2022
NCT05827068Completed698Est. Nov 2023
NCT05333289Completed572Est. Nov 2022
+4 more trials
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
1
VXA-A1.1Phase 11 trial
Active Trials
NCT01761123CompletedEst. Oct 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisCell-derived influenza vaccine
ModernamRNA-1010
ModernamRNA-1010
ModernamRNA-1010
ModernamRNA-1010
Novartistrivalent split influenza vaccine
NovartisTIV
NovartisInfluenza Vaccine
NovartisBEGRIVAC
BioCryst PharmaceuticalsPeramivir
Novartisinactivated split influenza vaccine
Novartistrivalent split influenza vaccine
Novartistrivalent split influenza vaccine
Novartisinactivated split influenza vaccine
NovartisMF59C.1-adjuvanted subunit influenza vaccine

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 91,994 patients across 23 trials

NCT00560066NovartisCell-derived influenza vaccine

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Start: Nov 2007Est. completion: Jul 20081,398 patients
Phase 4Completed
NCT06602024ModernamRNA-1010

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

Start: Sep 2024Est. completion: Aug 202540,817 patients
Phase 3Completed
NCT05827978ModernamRNA-1010

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Start: Apr 2023Est. completion: Jun 20248,411 patients
Phase 3Completed
NCT05566639ModernamRNA-1010

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Start: Sep 2022Est. completion: Jan 202422,502 patients
Phase 3Completed
NCT05415462ModernamRNA-1010

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Start: Jun 2022Est. completion: Sep 20236,102 patients
Phase 3Completed
NCT01346592Novartistrivalent split influenza vaccine

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Start: Apr 2011Est. completion: Jul 20126,104 patients
Phase 3Completed
NCT01209780NovartisTIV

Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

Start: Sep 2010Est. completion: Sep 20113,116 patients
Phase 3Completed
NCT01161264NovartisInfluenza Vaccine

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Start: Jul 2010Est. completion: Jul 2010126 patients
Phase 3Completed
NCT01147081NovartisBEGRIVAC

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Start: Jun 2010Est. completion: Jul 2010142 patients
Phase 3Completed
NCT00957996BioCryst PharmaceuticalsPeramivir

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Start: Oct 2009Est. completion: Aug 2011234 patients
Phase 3Completed
NCT00945841Novartisinactivated split influenza vaccine

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010

Start: Jun 2009Est. completion: Jun 2009126 patients
Phase 3Completed
NCT00735410Novartistrivalent split influenza vaccine

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Start: Jun 2008Est. completion: Jul 2008134 patients
Phase 3Completed
NCT00498303Novartistrivalent split influenza vaccine

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Start: Jun 2007120 patients
Phase 3Completed
NCT00354016Novartisinactivated split influenza vaccine

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

Start: Jul 2006125 patients
Phase 3Completed
NCT01342796NovartisMF59C.1-adjuvanted subunit influenza vaccine

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Start: May 2011Est. completion: Feb 201284 patients
Phase 2Completed
NCT01344057NovartisSeasonal Influenza Vaccine

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Start: May 2011Est. completion: Jun 201163 patients
Phase 2Completed
NCT01151059NovartisTrivalent subunit inactivated flu vaccine, Formulation 2010-2011

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Start: Jun 2010Est. completion: Jul 2010138 patients
Phase 2Completed
NCT01152814NovartisSeasonal flu vaccine

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011

Start: Jun 2010Est. completion: Jul 201064 patients
Phase 2Completed
NCT01123954NovartisSeasonal flu vaccine

Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers

Start: Jan 2010Est. completion: Apr 201033 patients
Phase 2Completed
NCT05827068ModernamRNA-1011.1

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Start: Mar 2023Est. completion: Nov 2023698 patients
Phase 1/2Completed
NCT05333289ModernamRNA-1030

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Start: Apr 2022Est. completion: Nov 2022572 patients
Phase 1/2Completed
NCT04956575ModernamRNA-1010

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Start: Jul 2021Est. completion: Sep 2022885 patients
Phase 1/2Completed
NCT01761123VaxartVXA-A1.1

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

Start: Jan 2013Est. completion: Oct 2014
Phase 1Completed

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
8h ago
$179K - $237K/yr

Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation

Gilead Sciences
United States - Field
20h ago
$317K - $411K/yr

Sr. Engineer, Process Systems (Contract)

VaxCyte
Visp, Valais, Switzerland
23h ago

Contract Senior Research Associate, Protein Science

Keros Therapeutics
Lexington, Massachusetts, United States
Yesterday

Director, Health Economics & Outcomes Research (HEOR)

VaxCyte
San Carlos, California, United States
Yesterday
$242K - $282K/yr

Senior Manager, Contract Account Performance Specialist, Contract Strategy

Pfizer
Remote
Yesterday
$124K - $207K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs — potential near-term approvals
Vaccine is the dominant modality (53% of programs)
4 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)